Yasuaki Anami
Senior Scientist CrossBridge Bio
Yasuaki Anami, PhD, is a senior scientist of CrossBridge Bio, where he is leading conjugation and linker chemistry. Before joining CrossBridge Bio, as an academia he developed microbial transglutaminase mediated branched linkers conjugation and glutamic acid contained tripeptide linker that can maximize ADC’s potential including safety and efficacy. With those technologies, he is developing stable and effective dual-drug ADCs with entire CrossBridge Bio team.
Seminars
- Leveraging the next‑generation EGCit linker to achieve enhanced plasma stability, reduced off‑target uptake, and rapid intracellular release, ensuring controlled delivery of multiple payloads with minimal systemic toxicity
- Employing microbial transglutaminase–based site‑specific conjugation and modular click‑chemistry assembly to achieve uniform DAR, high homogeneity, and orthogonal installation of distinct payloads without cross‑reactivity
- Advancing dual‑payload ADCs, including the branched‑linker TROP‑2 candidate CBB‑120, to simultaneously target tumor heterogeneity and resistance pathways through synergistic mechanisms of action
As tumor heterogeneity and acquired resistance continue to limit the durability of single-payload ADCs, dual-payload
strategies are emerging as a powerful approach to deliver complementary mechanisms of action within a single, precisely engineered construct.
Join leading experts as they discuss how orthogonal chemistry, enzymatic precision, and innovative linker design can converge to create stable, scalable, and clinically translatable dual-payload ADC platforms by:
- Balancing combinatorial potency with molecular precision, examining how one-step multi-payload conjugation, glycan directed strategies, and orthogonal enzymatic chemistries can achieve controlled payload ratios and spatial placement to address tumor heterogeneity without compromising stability
- Redefining site-specific conjugation as the foundation for dual-payload success, debating how high-precision enzymatic platforms and EGCit-enabled linker systems can deliver homogeneous constructs with optimized DAR distribution, improved pharmacokinetics, and reduced off-target toxicity
- Designing linker architectures to strategically combat resistance, evaluating how innovative cleavable, traceless, or modality-specific linkers can coordinate sequential or complementary payload release, integrate novel payload classes, and maintain manufacturability while expanding the therapeutic index
